Fawzy Rasha, Serag Mounir, Soliman Amal, Elwia Sania, Mojahed Samia
Department of Rheumatology, Benha University, Benha, Egypt.
Department of Biochemistry, Benha University, Benha, Egypt.
Arch Rheumatol. 2022 May 6;37(4):527-535. doi: 10.46497/ArchRheumatol.2022.9307. eCollection 2022 Dec.
To explore the ability to use urinary level of plasmin as an indicator for renal affection and activity in systemic lupus erythematosus (SLE) patients.
Between April 2020 and October 2020, urine samples from 50 SLE patients (2 males, 48 females; mean age: 35.5±8.1 years; range, 22 to 39 years) and 20 age- and sex-matched healthy controls (2 males, 18 females; mean age: 34.1±6.5 years; range, 27 to 38 years) were collected. The patients were divided into two groups according to the presence or absence of renal manifestations as those with renal disease (n=28) and those without renal disease (n=22). The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), renal activity (rSLEDAI), and Systemic Lupus International Collaborating Clinics Damage Index (SLICC-DI) scores were calculated. Renal biopsy was performed to patients with active lupus nephritis (LN). The activity index (AI) and Chronicity Index (CI) were scored.
There was a highly statistically significant difference in the mean urinary plasmin levels between SLE cases and the control group (88.9±42.6 ng/mL 21.3±26.8 ng/mL, respectively; p<0.001). A significant elevation was observed (p<0.05) in patients with LN (97.9±46.6 ng/mL) than without (42.7±12.7 ng/mL), particularly in patients with active renal involvement (82.9±26.6 ng/mL) than patients with inactive renal disease (63.2±15.5 ng/mL). There were significant positive correlations between the mean urinary plasmin levels and inflammatory markers, SLEDAI, and rSLEDAI scores.
Urinary level of plasmin is significantly elevated among SLE cases, particularly in those with active LN. The remarkable association between urinary plasmin level and various activity status implies that urinary plasmin can be used as a beneficial marker to monitor lupus nephritis flare.
探讨尿纤溶酶水平作为系统性红斑狼疮(SLE)患者肾脏受累及活动指标的应用能力。
收集2020年4月至2020年10月期间50例SLE患者(男2例,女48例;平均年龄:35.5±8.1岁;范围22至39岁)及20例年龄和性别匹配的健康对照者(男2例,女18例;平均年龄:34.1±6.5岁;范围27至38岁)的尿液样本。根据是否存在肾脏表现将患者分为两组,即患有肾脏疾病的患者(n = 28)和未患有肾脏疾病的患者(n = 22)。计算系统性红斑狼疮疾病活动指数(SLEDAI)、肾脏活动指数(rSLEDAI)和系统性红斑狼疮国际协作临床损伤指数(SLICC - DI)评分。对活动性狼疮性肾炎(LN)患者进行肾活检。对活动指数(AI)和慢性指数(CI)进行评分。
SLE患者组与对照组的平均尿纤溶酶水平存在高度统计学显著差异(分别为88.9±42.6 ng/mL和21.3±26.8 ng/mL;p < 0.001)。LN患者(97.9±46.6 ng/mL)的尿纤溶酶水平显著高于无LN患者(42.7±12.7 ng/mL)(p < 0.05),特别是有活动性肾脏受累的患者(82.9±26.6 ng/mL)高于无活动性肾脏疾病的患者(63.2±15.5 ng/mL)。平均尿纤溶酶水平与炎症标志物、SLEDAI及rSLEDAI评分之间存在显著正相关。
SLE患者尿纤溶酶水平显著升高,尤其是活动性LN患者。尿纤溶酶水平与各种活动状态之间的显著关联表明尿纤溶酶可作为监测狼疮性肾炎发作的有益标志物。